ArriVent BioPharma, Inc. cotiza a 16.09 USD y tiene una capitalización bursátil de $793M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in mul…
| Periodo | 2026-11 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.96 | $-0.78 | $-0.83 |
| Estimado | $-1.08 | $-0.89 | $-0.85 | $-0.78 |
| Sorpresa | — | -7.9% | +8.2% | -6.4% |
| Métrica | AVBP | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -54.1% | -40.4% | -13.7% |
| ROA | -49.9% | -32.0% | -17.9% |
| Current Ratio | 12.83 | 2.84 | +9.99 |
| Debt / Equity | — | 0.28 | — |